It was initially thought that HER2 amplification and overexpression were stable over the course of disease and concordant between primary tumour and metastases, and therefore patients with low levels of expression at first presentation of breast cancer are rarely given anti-HER2 (trastuzumab) treatment. The gene discussed is ERBB2; the disease is breast cancer.